APA

Floc'h N., Martin M. J., Riess J. W., Orme J. P., Staniszewska A. D., Ménard L., Cuomo M. E., O'Neill D. J., Ward R. A., Finlay M. R. V., McKerrecher D., Cheng M., Vang D. P., Burich R. A., Keck J. G., Gandara D. R., Mack P. C. & Cross D. A. E. (20190708). Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. : Molecular cancer therapeutics.

Chicago

Floc'h Nicolas, Martin Matthew J, Riess Jonathan W, Orme Jonathan P, Staniszewska Anna D, Ménard Ludovic, Cuomo Maria Emanuela, O'Neill Daniel J, Ward Richard A, Finlay M Raymond V, McKerrecher Darren, Cheng Mingshan, Vang Daniel P, Burich Rebekah A, Keck James G, Gandara David R, Mack Philip C and Cross Darren A E. 20190708. Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. : Molecular cancer therapeutics.

Harvard

Floc'h N., Martin M. J., Riess J. W., Orme J. P., Staniszewska A. D., Ménard L., Cuomo M. E., O'Neill D. J., Ward R. A., Finlay M. R. V., McKerrecher D., Cheng M., Vang D. P., Burich R. A., Keck J. G., Gandara D. R., Mack P. C. and Cross D. A. E. (20190708). Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. : Molecular cancer therapeutics.

MLA

Floc'h Nicolas, Martin Matthew J, Riess Jonathan W, Orme Jonathan P, Staniszewska Anna D, Ménard Ludovic, Cuomo Maria Emanuela, O'Neill Daniel J, Ward Richard A, Finlay M Raymond V, McKerrecher Darren, Cheng Mingshan, Vang Daniel P, Burich Rebekah A, Keck James G, Gandara David R, Mack Philip C and Cross Darren A E. Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. : Molecular cancer therapeutics. 20190708.